My personal preference is to float 10 million shares, but HB, based upon his recent comments, seems to be leaning towards partnering.
In either event, we will know for sure in the next 90 days or so.
Another advantage of partnering Pona in Europe and or Asia, is that with someone selling Pona for us in Europe and Asia and Merck and Aria
selling Rida and Ariad selling Pona in the USA, Ariad should gain valuable selling experience to draw up if "113" turns out to be as valuable a drug as many here believe it will be. Then we will have the drug the sales force the experience and the money to operate, sans partners, with "113".
As usual, JMHO
